| Title: | Association of gene mutations with clinicopathologic features in patients with external auditory canal squamous cell carcinoma |
| Authors: | Morita, Shinya Browse this author |
| Kano, Satoshi Browse this author →KAKEN DB |
| Hatanaka, Kanako C. Browse this author |
| Hatanaka, Yutaka Browse this author |
| Suzuki, Takayoshi Browse this author |
| Fukuda, Atsushi Browse this author |
| Hoshino, Kimiko Browse this author |
| Fujiwara, Keishi Browse this author |
| Nakamaru, Yuji Browse this author →KAKEN DB |
| Homma, Akihiro Browse this author →KAKEN DB |
| Keywords: | External auditory canal cancer |
| Squamous cell carcinoma |
| Next-generation sequencing |
| Gene mutations |
| Clinicopathologic features |
| Issue Date: | 1-Sep-2022 |
| Publisher: | Springer |
| Journal Title: | International journal of clinical oncology |
| Volume: | 27 |
| Issue: | 9 |
| Start Page: | 1394 |
| End Page: | 1403 |
| Publisher DOI: | 10.1007/s10147-022-02191-z |
| Abstract: | Background External auditory canal squamous cell carcinoma (EACSCC) is a rare form of malignant tumor. Due to the extremely limited understanding of the genomic landscape in EACSCC, the association between gene mutations and clinicopathologic features remains unclear. This study aimed to explore somatic gene mutations associated with the clinicopathological features in patients with EACSCC, and to identify the candidate gene mutations for predicting survival outcome in EACSCC. Methods Twenty-two tissue samples obtained from patients with EACSCC were analyzed for genetic mutations based on targeted next-generation sequencing and genetic expression based on IHC staining to investigate the driver of tumorigenesis and/or the candidates of genes for predicting clinical outcome in EACSCC. Results Gene alterations were most frequently observed in TP53 (59.1%), followed by CREBBP (9.1%). TP53 mutations showed significant correlation with T classification (P = 0.027) and p53 expression phenotype (P < 0.001). The 5-year overall survival (OS) rates for EACSCC patients with TP53 mutations and wild-type TP53 were 45.0% and 75.0%, respectively. Multivariable analysis using the Cox proportional hazards model demonstrated that TP53 mutations were independent predictors of OS rates for EACSCC patients (P = 0.007). Conclusion This study has suggested that TP53 mutations have potential for use as a biomarker for identifying individuals at high risk of developing tumors and for predicting survival outcome in EACSCC. IHC staining for p53 might play a useful role as screening tool for detecting TP53 mutations in patients with EACSCC. |
| Rights: | This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10147-022-02191-z |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/90369 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
